Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
303.05
-0.59 (-0.19%)
At close: Jun 5, 2026, 4:00 PM EDT
300.00
-3.05 (-1.01%)
After-hours: Jun 5, 2026, 6:40 PM EDT
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,500 employees as of December 31, 2025. The number of employees increased by 270 or 12.11% compared to the previous year.
Employees
2,500
Change (1Y)
270
Growth (1Y)
12.11%
Revenue / Employee
$1,714,769
Profits / Employee
$215,196
Market Cap
40.46B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,500 | 270 | 12.11% |
| Dec 31, 2024 | 2,230 | 130 | 6.19% |
| Dec 31, 2023 | 2,100 | 98 | 4.90% |
| Dec 31, 2022 | 2,002 | 337 | 20.24% |
| Dec 31, 2021 | 1,665 | 212 | 14.59% |
| Dec 31, 2020 | 1,453 | 130 | 9.83% |
| Dec 31, 2019 | 1,323 | 258 | 24.23% |
| Dec 31, 2018 | 1,065 | 316 | 42.19% |
| Dec 31, 2017 | 749 | 235 | 45.72% |
| Dec 31, 2016 | 514 | 145 | 39.30% |
| Dec 31, 2015 | 369 | 113 | 44.14% |
| Dec 31, 2014 | 256 | 91 | 55.15% |
| Dec 31, 2013 | 165 | 36 | 27.91% |
| Dec 31, 2012 | 129 | 13 | 11.21% |
| Dec 31, 2011 | 116 | -56 | -32.56% |
| Dec 31, 2010 | 172 | -6 | -3.37% |
| Dec 31, 2009 | 178 | 8 | 4.71% |
| Dec 31, 2008 | 170 | 41 | 31.78% |
| Dec 31, 2007 | 129 | 7 | 5.74% |
| Dec 31, 2006 | 122 | 28 | 29.79% |
| Dec 31, 2005 | 94 | 23 | 32.39% |
| Dec 31, 2004 | 71 | 11 | 18.33% |
| Dec 31, 2003 | 60 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,088 |
| Incyte | 2,844 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
ALNY News
- 3 days ago - Alnylam, Inceptive sign up to $2 billion AI drug discovery deal - Reuters
- 3 days ago - Alnylam, Inceptive form strategic AI collaboration - TheFly
- 3 days ago - Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics - Business Wire
- 18 days ago - Alnylam Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 19 days ago - Alnylam Issues 2025 Corporate Responsibility Report - Business Wire
- 19 days ago - Alnylam initiated with a Buy at Citi - TheFly
- 24 days ago - Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 26 days ago - Alnylam announces new analyses from HELIOS-B study of vutrisiran - TheFly